GSK Plans U.K.-Wide Bexsero Vaccination Campaign, Sells Other Meningitis Vaccines To Pfizer
This article was originally published in The Pink Sheet Daily
Two vaccination campaigns will start in the U.K. this summer, one featuring GSK’s meningitis B vaccine Bexsero, recently acquired from Novartis, and the other vaccines against a growing threat from W strain meningococcus, as GSK plans to divest its own meningitis vaccines to Pfizer.
You may also be interested in...
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.